Conese M, Olson D, Blasi F
Department of Biological and Technological Research, San Raffaele Research Institute, Milano, Italy.
J Biol Chem. 1994 Jul 8;269(27):17886-92.
After binding to its receptor (uPAR), active cell-surface urokinase (uPA) is not internalized while the complex formed by uPA with plasminogen activator inhibitor type 1 (PAI-1) is internalized and degraded. Internalization and degradation require binding to uPAR and subsequently an interaction with the alpha 2-macroglobulin receptor (alpha 2-MR). To analyze the generality of this mechanism, we studied the internalization of uPA by recombinant protease nexin-1 (rPN-1), an inhibitor of thrombin, uPA, and plasmin. 125I-uPA.rPN-1 complexes bound specifically to uPAR; internalization occurred efficiently, and its time course was essentially the same as for uPA.PAI-1. Internalization required binding to uPAR since it could be blocked by the anti-uPAR monoclonal antibodies, by the uPAR antagonist amino-terminal fragment of uPA, and by the removal of uPAR by the treatment of cells with phosphatidylinositol-specific phospholipase C. As for uPA.PAI-1, the internalization of uPA.rPN-1 also required alpha 2-MR, since it could be inhibited by the 39-kDa alpha 2-macroglobulin receptor/low density lipoprotein receptor-associated protein, a ligand for the alpha 2-MR. Finally, we show by ligand blot analysis that the uPA.rPN-1 complex, like uPA.PAI-1 but unlike free uPA, bound specifically to both uPAR and alpha 2-MR.
活性细胞表面尿激酶(uPA)与受体(uPAR)结合后不会被内化,而uPA与1型纤溶酶原激活物抑制剂(PAI-1)形成的复合物会被内化并降解。内化和降解需要与uPAR结合,随后与α2-巨球蛋白受体(α2-MR)相互作用。为了分析这种机制的普遍性,我们研究了重组凝血酶、uPA和纤溶酶抑制剂凝血酶敏感蛋白-1(rPN-1)对uPA的内化作用。125I-uPA.rPN-1复合物特异性结合uPAR;内化有效发生,其时间进程与uPA.PAI-1基本相同。内化需要与uPAR结合,因为它可以被抗uPAR单克隆抗体、uPA的uPAR拮抗剂氨基末端片段以及用磷脂酰肌醇特异性磷脂酶C处理细胞去除uPAR所阻断。与uPA.PAI-1一样,uPA.rPN-1的内化也需要α2-MR,因为它可以被39-kDa的α2-巨球蛋白受体/低密度脂蛋白受体相关蛋白抑制,该蛋白是α2-MR的配体。最后,我们通过配体印迹分析表明,uPA.rPN-1复合物与uPA.PAI-1一样,但与游离uPA不同,它特异性结合uPAR和α2-MR。